Products - Arthritis | Topic

Showing 19 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Anakinra for treating Still’s disease (TA685)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 March 2021
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 February 2021
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 June 2021
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375) [ID2710]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
14 July 2021
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 July 2021
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 July 2021
Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus)
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
28 July 2021
Magnetic resonance therapy for knee osteoarthritis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
25 August 2021
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 September 2021
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 October 2021
Osteoarthritis: care and management (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
19 October 2022
High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Geniculate artery embolisation for pain from knee osteoarthritis
Status:
In development | In consultation
Programme:
Interventional procedures guidance
Consultation end date:
25 June 2021
Expected publication date:
TBC
Lateral elbow resurfacing for arthritis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Upadacitinib for treating active ankylosing spondylitis [ID3848]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Upadacitinib for previously treated moderate active rheumatoid arthritis [ID3878]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tofacitinib for treating active ankylosing spondylitis [ID3865]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Risankizumab for previously treated active psoriatic arthritis [ID1399]
Status:
Proposed
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Arthritis Products

Filter

Product type
1 selected

Guidance programme

Status

New and updated
1 selected

Showing 19 products

Anakinra for treating Still’s disease (TA685)

Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375) [ID2710]

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus)

Magnetic resonance therapy for knee osteoarthritis

Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

Tofacitinib for treating juvenile idiopathic arthritis [ID2718]

Osteoarthritis: care and management (update)

High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis

Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]

Geniculate artery embolisation for pain from knee osteoarthritis

Lateral elbow resurfacing for arthritis

Upadacitinib for treating active ankylosing spondylitis [ID3848]

Upadacitinib for previously treated moderate active rheumatoid arthritis [ID3878]

Tofacitinib for treating active ankylosing spondylitis [ID3865]

Risankizumab for previously treated active psoriatic arthritis [ID1399]

Arthritis Products

Filter

Product type1 selected

Guidance programme

Status

New and updated1 selected

Showing 19 products

Product type
1 selected

New and updated
1 selected